BioInvent's BI-1206 Triplet Achieves 83% Response Rate in Refractory NHL with Improved Safety vs. SOC (EHA 2026)

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

$BioInvent's BI-1206 Triplet Achieves 83% Response Rate in Refractory NHL with Improved Safety vs. SOC (EHA 2026)$

What matters in this story

1
BioInvent's BI-1206 triplet achieved an 81% objective response rate (ORR) in relapsed/refractory follicular lymphoma, matching recently approved competitors. — Matching the efficacy of approved standard-of-care combinations validates the drug's primary clinical utility and increases the likelihood of future approval.
+0.80
2
The BI-1206 triplet showed a serious adverse event rate of 14%, significantly lower than competing regimens which ranged from 29% to 56%. — Superior safety profiles are a key differentiator that can lead to preferred prescribing status over existing standard-of-care therapies.
+0.70
3
Treatment discontinuation due to adverse events for the BI-1206 triplet was only 3%, compared to 7%-19% for R2-based regimens. — Lower discontinuation rates suggest better patient adherence and a more viable commercial product profile.
+0.50
4

What matters in this story